Analyst: Partnership deals an option for Bavarian
The latest phase II data on Bavarian Nordic’s cancer vaccine CV-301 are great news, says analyst Frank H. Andersen. A later strategic portfolio assessment could lead to partnership deals.
by Stefan Singh Kailay
It is certainly very good news the Danish company Bavarian Nordic announced concerning its vaccine candidate on Wednesday. That is the brief assessment from analyst Frank H. Andersen, Jyske Bank, who has previously told Medwatch he was keeping a close eye on the drug.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Bavarian publishes promising cancer data
For abonnenter
.jpg&w=384&q=75)
